Codexis Revenue Jumps 91 Percent in Q2
(NASDAQ:CDXS), a biotechnology company specializing in enzyme engineering for pharmaceutical manufacturing, released its second quarter 2025 results on August 13, 2025. The headline news was an increase in revenue (GAAP) to $15.3 million, above analyst expectations of $14.09 million (GAAP). The net loss per share (GAAP) improved to ($0.16), also better than the estimated ($0.19) GAAP EPS. Management highlighted strong demand in its growing RNA therapeutics manufacturing segment, alongside expanded partnerships with key players in the industry. Overall, the period showed improved gross margins and commercial progress, although losses persisted and operational costs remained high.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Codexis develops and provides enzyme-based solutions for pharmaceutical manufacturing, focusing on platforms that make drug development more efficient and cost-effective. Its core business leverages proprietary enzyme engineering and optimization, which enables clients to synthesize pharmaceuticals and novel therapeutic products more sustainably and at larger scales.
Source Fool.com
